Sep 30, 2025 4:11 PM Eastern Daylight Time Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock Share WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intend ...

Group 1 - The article is authored by Terry Chrisomalis, who operates the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace [1] - The service offers a comprehensive analysis of various pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] - A two-week free trial is currently available for new subscribers, with a monthly subscription priced at $49 and an annual plan offering a 33.50% discount at $399 [1][2] Group 2 - The Biotech Analysis Central service includes live chat and a range of analysis and news reports aimed at assisting healthcare investors in making informed decisions [2] - The author has no current stock or derivative positions in any mentioned companies and does not plan to initiate any within the next 72 hours [3] - The article reflects the author's personal opinions and is not compensated by any company mentioned [3]

Study Overview - The Phase 2b RSVHR study (n=186) aimed to demonstrate a clinically meaningful reduction in symptom duration of at least ~1 day in high-risk adults treated with Zelicapavir [12] - The study's primary objective was to assess the time to resolution of RSV lower respiratory tract disease (LRTD) symptoms [15] - The study randomized 186 adults with COPD, congestive heart failure, asthma, or age ≥65 [15] Efficacy Results - Zelicapavir resulted in faster complete symptom resolution across multiple RiiQTM measures [33] - In the HR3 population, Zelicapavir showed a 3-day faster time to complete resolution of LRTD symptoms, a 6.7-day faster time to complete resolution of all RSV symptoms, and a 7.2-day faster time to complete resolution of total RiiQ 29 parameters compared to placebo [34, 39] - The study showed a statistically significant 2-day faster symptom resolution by PGI-S compared to placebo in both the efficacy (p=0.0446) and HR3 populations (p=0.0465) [36, 38, 40] Safety and Additional Endpoints - The study exhibited a favorable safety profile, with adverse events (AEs) being similar between the Zelicapavir and placebo groups [29, 31] - The hospitalization rate was lower for patients treated with Zelicapavir: 1.7% (2/115) vs 5.0% (3/60) on placebo [42] - A greater proportion of patients treated with Zelicapavir had undetectable viral load at the end of treatment in the Efficacy Population: 23.5% (27/115) vs 10.0% (6/60) (p=0.0198) and in the HR3 Population: 23.9% (22/92) vs 10.0% (5/50) (p=0.0292) [43] - Zelicapavir showed a viral load decline of 0.7 log at the end of treatment in the HR3 population [44, 45]

Core Insights - Merus NV's shares increased by 38.2% to $95.21 following Genmab's announcement of an $8 billion all-cash acquisition deal, which includes the addition of the breakthrough therapy Petosemtamab to Genmab's late-stage pipeline [1] Gainers - Steakholder Foods Ltd rose 92% to $8.32 after announcing an agreement to acquire Twine Solutions [4] - JFB Construction Holdings surged 77.4% to $12.15 following a $44 million private placement announcement [4] - Plus Therapeutics gained 24.3% to $0.77 after securing a national coverage agreement with UnitedHealthcare for its CNSide assay [4] - Avalo Therapeutics rose 24.1% to $13.40 after a previous decline of 6% [4] - Enanta Pharmaceuticals gained 22.7% to $9.69 ahead of presenting topline results from its Phase 2b study of Zelicapavir for RSV [4] - Canopy Growth Corp jumped 19.4% to $1.60 [4] - Zura Bio Ltd gained 18.3% to $2.85 after a 15% increase on Friday [4] - Tilray Brands surged 17.4% to $1.35, with first-quarter financial results to be announced on October 9 [4] - Larimar Therapeutics jumped 16.4% to $5.93, with an update on the Nomlabofusp program scheduled for September 2 [4] Losers - MoonLake Immunotherapeutics dipped 86.3% to $8.50 despite achieving statistically significant results in its Phase 3 VELA trials [4] - Maris Tech fell 37.3% to $2.62 after reporting a H1 loss of 30 cents per share [4] - Sunrise New Energy Co Ltd shares dipped 28.1% to $0.88 after a previous 10% gain [4] - Cycurion Inc declined 15.5% to $0.28 after a significant drop of over 30% on Friday [4] - bioAffinity Technologies dipped 14.4% to $4.53 after a 55% increase on Friday [4] - Youxin Technology Ltd fell 13.9% to $0.058 following a 1-for-80 reverse split announcement [4] - Top KingWin Ltd declined 12.8% to $4.07 after a previous 48% increase [4] - Cellectis SA fell 10.4% to $3.01 [4] - Quantum-Si Inc decreased 10.1% to $1.34 after filing for a mixed shelf of up to $300 million [4] - Penguin Solutions Inc fell 8.4% to $24.00 [4]

Enanta Pharmaceuticals Inc. (ENTA) will hold a conference call and webcast on Monday, September 29, 2025, at 8:30 a.m. ET to share topline results from its RSVHR study.RSVHR is a phase 2b trial evaluating its lead drug candidate Zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults.Respiratory syncytial virus (RSV) causes severe lung infections, including bronchiolitis and pneumonia. High-risk populations include premature babies, young infants, and children. In the U.S. al ...